Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $1.05 billion aggregate principal amount of its 0.250% senior convertible notes due 2025.
Headquartered in San Diego, California, DexCom, Inc. is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring systems for use by people with diabetes and by healthcare providers.
The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jeffrey Gould and associate Dongbiao Shen. The tax team included partner Michael Farber and associate Shay Moyal. Partner Pritesh P. Shah and associate Jennifer Leather provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.